Economics
Bayer Sees 8% Growth in Drug Sales on New Medicines
This article is for subscribers only.
Bayer AG forecast 8 percent annual growth in pharmaceutical revenue through 2016 on demand for new medicines.
Bayer predicted 6 percent growth for its crop-science business, the company said in a statement today as executives meet with investors and analysts in Leverkusen, Germany, where the 150-year-old company is based. No specific forecast was issued for the material-science unit, which some analysts speculate may be sold or spun off.